TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of Recurrent or Refractory Childhood CML
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Treatment options for children with recurrent or refractory chronic myeloid leukemia (CML) may include the following:
Alternative tyrosine kinase inhibitor (TKI) therapy such as dasatinib, nilotinib, or bosutinib.
Source links and citations
Allogeneic hematopoietic stem cell transplant (HSCT).
Source links and citations
Continue within this section
Preserved source evidence · Not medical advice